Advertisement
UK markets close in 2 hours 5 minutes
  • FTSE 100

    8,182.35
    +40.20 (+0.49%)
     
  • FTSE 250

    20,351.46
    +191.74 (+0.95%)
     
  • AIM

    777.95
    +3.02 (+0.39%)
     
  • GBP/EUR

    1.1827
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2697
    -0.0007 (-0.06%)
     
  • Bitcoin GBP

    51,153.66
    -587.60 (-1.14%)
     
  • CMC Crypto 200

    1,347.67
    -41.73 (-3.00%)
     
  • S&P 500

    5,473.23
    +41.63 (+0.77%)
     
  • DOW

    38,778.10
    +188.94 (+0.49%)
     
  • CRUDE OIL

    80.53
    +0.20 (+0.25%)
     
  • GOLD FUTURES

    2,332.40
    +3.40 (+0.15%)
     
  • NIKKEI 225

    38,482.11
    +379.67 (+1.00%)
     
  • HANG SENG

    17,915.55
    -20.57 (-0.11%)
     
  • DAX

    18,094.73
    +26.52 (+0.15%)
     
  • CAC 40

    7,613.49
    +41.92 (+0.55%)
     

Insulet to Present at the Jefferies Global Healthcare Conference

ACTON, Mass., May 28, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time).

To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone or the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

ADVERTISEMENT

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240527181999/en/

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com